Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 901–1,000 of 1,000
Deep Learning-based Modeling for Preclinical Drug Safety AssessmentPreprint
Jaume, G., de Brot, S., Song, A. H., Williamson, D. F. K., Oldenburg, L., Zhang, A., Chen, R. J., Asín, J., Blatter, S., Dettwiler, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.20.604430 · Cited by 12
“A key challenge in this transition is assessing toxicity, which accounts for 82% of drug development discontinuation at the preclinical stage 2,3 .”
BackgroundStorey, C. M., Cheng, M., Altai, M., Park, J. E., Tran, J., Lueong, S., Thorek, D. L. J., Mao, L., Zedan, W., Yuen, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.22.624939 · Cited by 5
Non-invasive quantification of viability in liver spheroids using deep learning
Dubinsky, D., Harel, S., Bein, A., Nyska, A., Ya’ari, S., Koc, B., Anas, F., Bentwich, I., & Wolf, L. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1797474 · Cited by 6
“Among the primary safety concerns associated with drugs is the risk of liver toxicity, specifically known as Drug-Induced Liver Injury (DILI), which is a major cause of drug withdrawal and failure in clinical trials (Watkins, 2011; Cook et al., 2014).”
Huang, H., Ji, F., Hu, C., Huang, J., Liu, F., Han, Z., Liu, L., Cao, M., & Fu, G. (2024) · Journal of Pain · doi:10.1016/j.jpain.2024.104610 · Cited by 4
Zhang, M., Vuist, I. M., Rottschäfer, V., & de Lange, E. C. M. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106883 · Cited by 4
Garzya, V., Rustici, G., Diethe, T., Blomgren, P., Mian, N., MacPherson, J. I., Constable, H., Port, R. J., & Weatherall, J. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104527 · Cited by 4
Next-generation lung-cancer-on-a-chip: Toward personalized therapy, AI, and CRISPR-driven models
Hossain, N. S., Tasnim, N., Ferdoush, J., Roy, A., Saha, S. C., & Saha, A. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104604 · Cited by 4
Delivery science: Its increasing importance for the next generation of medicines
Ashford, M. B., & Bak, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114663 · Cited by 5
A public–private collaboration model for clinical innovation
Wegner, C. D., Mount, B. A., & Colvis, C. M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13293 · Cited by 5
“Beyond the new therapeutic use idea, investigators brought three crucial additional aspects to the potential collaboration: (1) expertise in the disease beyond that existing within the pharmaceutical partner, (2) access to patients at their clinic/institution and/or network, and (3) disease relevant symptom or biomark…”
BackgroundSubgroup analysis and adaptive experiments crave for debiasing
Wang, J., & He, X. (2023) · Wiley Interdisciplinary Reviews Computational Statistics · doi:10.1002/wics.1614 · Cited by 4
“The subgroup selection bias is a major culprit (Cook et al., 2014; Guo & He, 2021), because such bias may lead to an overly optimistic evaluation of the selected subgroup obtained from the exploratory subgroup analysis.”
BackgroundRaniga, K., Stebbeds, W., Shivalingam, A., Pemberton, M., & Denning, C. N. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.10.006 · Cited by 7
Aebi, J. D., Atz, K., Ametamey, S. M., Benz, J., Blaising, J., Butini, S., Campiani, G., Carreira, E. M., Collin, L., de Lago, E., et al. (2024) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2024.499 · Cited by 7
Mechanopharmacology: in vitro techniques to advance drug discovery
Zielinski, J., Lee, C. H., Gunatilaka, A., Gao, X., & Stewart, A. G. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17401 · Cited by 7
“…– helix ARNT-like protein 1; ECM, extracellular matrix; PDMS, polydimethylsiloxane; PER, gene repressors period; TCP, tissue culture plastic; 2D, two-dimensional; 3D, three-dimensional. because of lack of efficacy, yet only 6% failed for the same reason in the preclinical phase (Cook et al., 2014).”
Tietze, L., Urbano, L., Eisenmann, S., Schwarzinger, J., Kollan, J., Forbes, B., Dailey, L. A., & Hädrich, G. (2025) · Pharmaceutical Research · doi:10.1007/s11095-024-03806-y · Cited by 4
Best Practices and Recommendations for Non-Liquid Matrices Bioanalysis
Vazvaei-Smith, F., Li, W., Barnaby, O. S., Bhardwaj, S., Dong, J. I., Dumont, C., Fernández‐Metzler, C., Geist, B. J., Hassanein, M., Hays, A. L., et al. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01033-w · Cited by 4
“Understanding the drug exposure at the site of action is a major determinant of the therapeutics’ success in phase II clinical trials and their progression to phase III (9, 10).”
MEMS in Twenty-First-Century Healthcare
Noushin, T., Parvez, M. S., Biswas, P., Bhuiyan, M. E. H., Rumon, M. A. A., & Tabassum, S. (2025) · Springer tracts in electrical and electronics engineering · doi:10.1007/978-981-96-4659-3_3 · Cited by 9
Adler, M., Leich, E., Ellinger-Ziegelbauer, H. C., Hewitt, P. G., Dekant, W., Rosenwald, A., & Mally, A. (2014) · Toxicology · doi:10.1016/j.tox.2014.10.007 · Cited by 3
“Hepatotoxic side effects account for a considerable fraction of project failures due to safety issues in drug development (Cook et al., 2014; Guengerich, 2011).”
BackgroundBridging academic science and clinical research in the search for novel targeted anti-cancer agents.
Matter, A. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0079 · Cited by 5
Floc’h, N., Guerriero, M. L., Ramos‐Montoya, A., Davies, B. R., Cairns, J., & Karp, N. A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036160 · Cited by 4
Watanabe, K., Murakami, M., Masuyama, K., Ishiguro, C., & Matsuda, T. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4662 · Cited by 4
“cardiovascular toxicity was the most common cause of drug development failure during the non‐clinical stage.(15) Target ARs with lower NPVs included abnormal hepatic function, anaphylactoid reaction, interstitial lung disease, jaundice, shock, and rhabdomyolysis.”
BackgroundKuepfer, L. (2019) · SVU- International Journal of Veterinary Sciences · doi:10.21608/svu.2019.14193.1020 · Cited by 4
“The majority of these project terminations are due to safety reasons (82% in the preclinical phase and 62% in phase I, respectively) (Cook et al. 2014).”
BackgroundWelsh, N. J., Gewinner, C. A., Mistry, K., Koglin, M., Cooke, J., Butler, M., Powney, B., Roberts, M., Staddon, J. M., & Schapira, A. H. V. (2019) · Haematologica · doi:10.3324/haematol.2019.224717 · Cited by 4
“Finally, current thinking cites the inappropriate patient stratification as a contributing factor to the failure of clinical trials for disease-modifying compounds used for the treatment of nervous system disorders (17-19).”
BackgroundPsychiatric Drug Discovery and Development
Shahid, M., Neill, J. C., & Hutchison, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.004 · Cited by 5
Preclinical in vivo Neurotoxicity Studies of Drug Candidates
Eremina, N. V., Колик, Л. Г., Ostrovskaya, R. U., & Durnev, A. D. (2020) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2020-10-3-164-176 · Cited by 4
“По некоторым оценкам, такие нежелательные реакции являются причиной около 34% случаев прекращения разработок на стадии клинических исследований [3].”
Álvarez-Machancoses, Ó., deAndrés‐Galiana, E. J., Fernández‐Martínez, J. L., & Kloczkowski, A. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-61401-0_55 · Cited by 4
Dutkiewicz, Z. (2020) · Physical Sciences Reviews · doi:10.1515/psr-2020-0034 · Cited by 4
Ewing, P., Oag, S., Lundqvist, A. J., Stomilovic, S., Stellert, I., Antonsson, M., Nunes, S. F., Andersson, P. U., Tehler, U., Sjöberg, C., et al. (2020) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2020.1637 · Cited by 4
A failure of forward translation? The case of neuroprotection
Lee, J., Rosand, J. M., & Cruchaga, C. (2021) · Vessel Plus · doi:10.20517/2574-1209.2020.72 · Cited by 9
“Recent retrospective reviews of the drug pipeline at several large pharmaceutical companies have revealed that if a drug target is independently confirmed using human genetics, the drug is twice as likely to attain FDA-approval[30,31].”
BackgroundMatsuda, N., Kinoshita, K., Okamura, A., Shirakawa, T., & Suzuki, I. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab061 · Cited by 4
Shimizu, Y., Sasaki, T., Takeshita, J., WATANABE, M., Shizu, R., Hosaka, T., & Yoshinari, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253855 · Cited by 5
Yanagida, S., Satsuka, A., Hayashi, S., Ono, A., & Kanda, Y. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00268 · Cited by 4
Considerations towards the better integration of epidemiology into quantitative risk assessment
Déglin, S. E., Burstyn, I., Chen, C. L., Miller, D. J., Gribble, M. O., Hamade, A. K., Chang, E. T., Avanasi, R., Boon, D., & Reed, J. (2022) · Global Epidemiology · doi:10.1016/j.gloepi.2022.100084 · Cited by 5
“However, there is growing concern about the ability of laboratory animals, particularly rodents, to accurately predict human outcomes [13,14].”
Machine Learning for Predicting Organ Toxicity
Liu, J., Guo, W., Dong, F., Patterson, T. A., & Hong, H. (2023) · Computational methods in engineering & the sciences · doi:10.1007/978-3-031-20730-3_22 · Cited by 5
Data science in drug discovery safety: Challenges and opportunities
Coltman, N. J., Roberts, R. A., & Sidaway, J. E. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231215890 · Cited by 4
Biomarker Methodologies: A NIMH Perspective
Grabb, M. C., & Brady, L. S. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69491-2_1 · Cited by 4
From academia to industry: a road more travelled
Pao, W. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx319 · Cited by 4
Data to Decisions: Creating a Culture of Model-Driven Drug Discovery
Brown, F. K., Kopti, F., Chang, C., Johnson, S. A., Glick, M., & Waller, C. L. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0124-2 · Cited by 4
“molecules, (4) resource-sparing approaches to identify any offtarget liabilities, (5) physicochemical properties for formulations, and (6) the mindset change to think dose-centrically from the beginning of all programs.”
CRISPR–Cas9 for Drug Discovery in Oncology
Guichard, S. M. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.006 · Cited by 4
Organs-on-Chips: a new paradigm for safety assessment of drug-induced thrombosis
Ng, P. R., Belgur, C., Barthakur, S., van der Meer, A. D., Hamilton, G. A., & Barrile, R. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.08.004 · Cited by 5
Use of SRS microscopy for imaging drugs
Steven, C. F., Chiarparin, E., Hulme, A. N., & Brunton, V. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85158-9.00030-0 · Cited by 5
Titus, S., & Sreejalekshmi, K. G. (2015) · CrystEngComm · doi:10.1039/c5ce01042j · Cited by 4
Head, S. A., & Liu, J. O. (2016) · Journal of Visualized Experiments · doi:10.3791/54529 · Cited by 6
Ferrero, E. (2018) · F1000Research · doi:10.12688/f1000research.13577.1 · Cited by 5
Combinatorial Approach in Rationale Design of Polymeric Nanomedicines for Cancer
Singh, A., & Amiji, M. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-50878-0.00013-6 · Cited by 7
Various Applications of 3D-Bioprinted Tissues/Organs Using Tissue-Specific Bioinks
Cho, D., Kim, B. S., Jang, J., Gao, G., Han, W., & Singh, N. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-32222-9_7 · Cited by 6
Fishburn, C. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800687-0.00032-3 · Cited by 4
Functional Cardiac Safety Evaluation of Novel Therapeutics
Valentin, J., Guth, B. D., Hamlin, R. L., Lainée, P., Sarazan, D., & Skinner, M. R. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch10 · Cited by 4
Development and Commercialization of Nanocarrier‐Based Drug Products
Ashford, M. B. (2016) · Wiley eBooks · doi:10.1002/9783527800681.ch29 · Cited by 4
Polypharmacology in Drug Discovery
Méndez‐Lucio, O., Naveja, J. J., Vite‐Caritino, H., Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527674381.ch1 · Cited by 4
First Deliveries of API Enabling Early Drug Development
Sather, A. C., & Douglas, J. J. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.4c00212 · Cited by 4
AI-driven Discovery of Morphomolecular Signatures in ToxicologyPreprint
Jaume, G., Peeters, T., Song, A. H., Pettit, R. W., Williamson, D. F. K., Oldenburg, L., Vaidya, A. J., de Brot, S., Chen, R. J., Thiran, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.19.604355 · Cited by 6
Botrugno, O. A., Bianchi, E., Bruno, J. M., Gallo, G. F. M., Felici, C., Sommella, E., Stefano, P. D., Giansanti, V., Rossella, V., Merciai, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.28.630600 · Cited by 5
Passini, E., Adedeji, A. O., Allen, R., Baldrick, P., Basak, J., Britton, L., Cotton, P., Harding, J., Holmes, T., Ljumanovic, N., et al. (2025) · Comparative Clinical Pathology · doi:10.1007/s00580-025-03642-5 · Cited by 3
“Monticello et al. (Monticello et al. 2017) estimated the prevalence of renal toxicity (as the target organ) in preclinical studies as only 5%, while the review of the AstraZeneca portfolio by Cook et al. (Cook et al. 2014) attributed 8% of preclinical and 9% of clinical failures to renal toxicity.”
Zhang, P. Z., Ballard, J. E., Fagiani, F. E., Smith, D. M., Gibson, C. R., & Yu, X. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00813 · Cited by 2
Bowen, T. J., Hall, A. R., Lloyd, G. R., Smith, M. J., Weber, R. J. M., Wilson, A., Pointon, A., & Viant, M. R. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04074-4 · Cited by 6
“Drug-induced structural cardiotoxicity (SCT) poses a significant challenge in the development of safe and efficacious medicines, evidenced by the large proportion of market withdrawals and project closures driven by cardiac safety concerns (Cook et al. 2014; Onakpoya et al. 2016).”
RXFP1, the relaxin receptor: Lost and found in translation
Lal, M., Eddy, S. F., Walentinsson, A., Hodgin, J. B., Hansen, P. B. L., Althage, M., & Kretzler, M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104483 · Cited by 3
Matsuda, N., Nagafuku, N., Matsuda, K., Ishibashi, Y., Taniguchi, T., Matsushita, Y., Miyamoto, N., Yoshinaga, T., & Suzuki, I. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf134 · Cited by 3
“Cardiotoxicity remains one of the most critical safety concerns in drug development and poses a significant threat to patient safety (Fung et al. 2001; Cook et al. 2014; Onakpoya et al. 2016; Mamoshina et al. 2021).”
Development of a genetic priority score to predict drug side effects using human genetic evidence
Duffy, Á., Chen, R. K., Stein, D. F., Park, J. K., Mort, M. E., Verbanck, M., Schlessinger, A., Itan, Y., Cooper, D. N., Jordan, D. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63762-y · Cited by 4
“First, we highlight several known examples of side effects where the direction ofgenetic effect supports the side effect observed in the Open Target or OnSIDES dataset (all with a SE-GPS >0.6, Supplementary Data 1).”
InfluentialMarkou, P., & Chan, T. H. (2025) · Management Science · doi:10.1287/mnsc.2023.03649 · Cited by 4
Mapping the developmental path for Parkinson’s disease therapeutics
Dhruv, N. T., Schwartz, S. R., Swanson‐Fischer, C., Cho, H. J., Corlew, R., Jakeman, L. B., Laboissonniere, L. A., Price, R., Sarraf, S. A., Sieber, B.-A., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01154-1 · Cited by 5
Johansson, L., Raggi, G., Cartwright, J., Lindqvist, J., Froment, L., Andersson, P., Betts, C. J., Hornberg, J. J., Hobi, N., Ollerstam, A., et al. (2026) · Archives of Toxicology · doi:10.1007/s00204-025-04269-9 · Cited by 4
“Indeed, even more established modalities such as small molecules are relatively often associated with adverse responses in the respiratory tract that may limit further development (Cook et al. 2014).”
Cai, C., Chen, Z., Wang, Z., Wu, L., Liu, Z., Fang, J., & Liu, A. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3166-8 · Cited by 3
“Therefore, early-stage evaluation of drug ADMET is critical to improve success rates, reduce costs, and enhance preclinical/ clinical safety by mitigating adverse reactions (Cook et al., 2014).”
Kaito, S., Sato, K., Sasaki, T., Hosaka, T., Shizu, R., Takeshita, J., & Yoshinari, K. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106075 · Cited by 3
Kalra, P., Kister, B., Fendt, R., Köster, M., Pulverer, J. E., Sahle, S., Kuepfer, L., & Kummer, U. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013509 · Cited by 4
“A truly comprehensive PK/PD understanding of a compound under in vivo conditions is hence difficult to achieve and inevitably inhibits several weaknesses which are also reflected by the continuously high attrition rates in pharmaceutical development [5].”
Tissue Engineering Platforms to Replicate the Tumor Microenvironment of Multiple Myeloma
Zhang, W., Lee, W. Y., & Zilberberg, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6539-7_12 · Cited by 3
Pre-clinical disease models in drug toxicity evaluation
Foster, M. L. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.06.001 · Cited by 3
Human genetics contributes to the understanding of disease pathophysiology and drug discovery
Sakaue, S., & Okada, Y. (2017) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2017.07.009 · Cited by 3
Bruckner, D. M., Connerney, J., & Dordick, J. S. (2018) · AIChE Journal · doi:10.1002/aic.16442 · Cited by 3
Wray, J., & Whitmore, A. V. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_7 · Cited by 3
Sherbetjian, E., Peters, S. A., & Petersson, C. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2132427 · Cited by 3
“Accurate prediction of VDss is therefore desired in the process of selecting a candidate drug as well as in the determination of the starting dose in clinical studies (Cook et al. 2014; Miller et al. 2019; Peters et al. 2020).”
BackgroundRana, P., Khan, S., Arat, S., Potter, D., & Khan, N. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00243 · Cited by 3
Strategies for translating proteomics discoveries into drug discovery for dementia
Halder, A., & Drummond, E. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373681 · Cited by 4
“Biological evidence that a protein target has a clear role in disease is a key predictor of success in drug development (Cook et al., 2014).”
Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades
Büssgen, M., & Büssgen, M. A. (2023) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-023-00612-6 · Cited by 3
Microsphere‐Enabled Modular Formation of Miniaturized In Vitro Breast Cancer Models
Wang, W., Zhang, L., O'Dell, R., Yin, Z., Yu, D., Chen, H., Liu, J., & Wang, H. (2023) · Small · doi:10.1002/smll.202307365 · Cited by 3
Menezes, P. D., Hecht, S., Hunter, A., & Gadegaard, N. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.148189 · Cited by 5
“This pursuit is notably urgent in the pharmaceutical industry, where despite great investments, the output of new drugs has remained mostly stagnant, resulting in a “ productivity crisis ” [3,4] with 89 % of new drugs failing clinical trials due to unpredicted human toxicity [5].”
Immunoaffinity proteomics for kidney injury biomarkers in male beagle dogs
Naboulsi, W., Planatscher, H., Schmidt, F. F., Steinhilber, A., Joos, T. O., Adedeji, A. O., McDuffie, J. E., & Poetz, O. (2023) · EXCLI journal · doi:10.17179/excli2023-6621 · Cited by 3
Gupta, B., Malviya, R., Srivastava, S., Ahmad, I. S., Rab, S. O., & Uniyal, P. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128305296240523112043 · Cited by 3
Jung, S., Kim, K., Wang, S., Han, M., & Lee, D. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.10.035 · Cited by 3
Olubamiwa, A. O., Ma, J., Dehanne, P., Noban, C., Angın, Y., Barberan, O., & Chen, M. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2514537 · Cited by 3
“Drug-induced liver injury (DILI) is responsible for the closure of a high number of drug discovery projects and is a common reason for the withdrawal of approved drugs from the market [2].”
Valentin, J., Bourcier, T., Chi, X., Delaunois, A. G., Foley, C. M., Henderson, K. A., Lainée, P., Leishman, D. J., Li, D., Pawluk, E., et al. (2025) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2025.107765 · Cited by 9
Experimental Medicine Approaches in CNS Drug Development
Paul, J. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00005-9 · Cited by 3
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Gerges, N. A., Stafford, A., Truong, K., Miron, Y., Winrow, B., Krause, B., Page, G., & Ghetti, A. (2022) · Journal of Visualized Experiments · doi:10.3791/64394 · Cited by 4
NINDS Translational Programs: Priming the Pump of Neurotherapeutics Discovery and Development
Ranganathan, R. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.026 · Cited by 3
The genome as pharmacopeia: Association of genetic dose with phenotypic response
Wadhawan, S., Runz, H., & Burchard, J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.02.005 · Cited by 3
Endogenous Toxins as Disease Initiating Events: Future Targets of Drug Discovery Research
Vangala, S. (2016) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2016.02.00036 · Cited by 3
“barriers, and shrinking productivity - pharmaceutical industry is experiencing a roller-coaster ride and unable to sustain their R&D programs for new drug discovery [1-5].”
BackgroundSystem Biology to Access Target Relevance in the Research and Development of Molecular Inhibitors
Catharina, L., de Menezes, M. A., & Carels, N. (2018) · Computational biology · doi:10.1007/978-3-319-74974-7_12 · Cited by 4
Development of Human Target Validation Classification that Predicts Future Clinical Efficacy
Karlsson, C., Greasley, P. J., Gustafsson, D., & Wåhlander, K. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250894 · Cited by 4
“In fact, selection of the most safe and potent molecule will still fail if the wrong target is selected (Cook et al., 2014).”
BackgroundInfluentialCowan, K., Macluskie, G., Finch, M., Palmer, C. N. A., Hair, J., Bylesjö, M., Lynagh, S., Brankin, P., McNeil, M., Low, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226564 · Cited by 3
Introducción a la Química Medicinal
Gavernet, L. (2021) · doi:10.35537/10915/114312 · Cited by 3
Ernst, S. W., Knight, R., Royle, J., & Stephenson, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00008-8 · Cited by 3
Genetics of Axial Spondyloarthritis
Brown, M. A., Xu, H., & Reveille, J. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-56800-5.00005-9 · Cited by 4
Biomarker-Based Drug Discovery with Reverse Translational Approach
Goyal, R. K., & Aggarwal, G. (2022) · Springer eBooks · doi:10.1007/978-981-16-9232-1_9 · Cited by 3
Marco‐Casanova, P., Lukashchuk, N., Lombardi, B., Munugalavadla, V., Frigault, M. M., Harrington, E. A., Barrett, J. C., & Pierce, A. J. (2021) · Journal of Visualized Experiments · doi:10.3791/60776-v · Cited by 3
An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials
Adeniyi, O., Ramamoorthy, A., Schuck, R. N., Sun, J., Wilson, J., Zineh, I., & Pacanowski, M. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1473 · Cited by 4
Marco‐Casanova, P., Lukashchuk, N., Lombardi, B., Munugalavadla, V., Frigault, M. M., Harrington, E. A., Barrett, J. C., & Pierce, A. J. (2021) · Journal of Visualized Experiments · doi:10.3791/60776 · Cited by 6
Challenges and Options for Drug Discovery
Kramer, W. (2016) · Wiley eBooks · doi:10.1002/9783527693405.ch6 · Cited by 4
Shipkova, P. A., Ciccimaro, E., & Olah, T. V. (2017) · Bioanalysis · doi:10.4155/bio-2017-0215 · Cited by 3
Project Selection and Success: Insights from the Drug Discovery ProcessPreprint
Markou, P., Kavadias, S., & Oraiopoulos, N. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3225056 · Cited by 3
Sharp Inference on Selected Subgroups in Observational StudiesPreprint
Guo, X., Wei, L., Wu, C., & Wang, J. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2102.11338 · Cited by 5
“When subgroups are identified post hoc from RCTs, it has been recognized in the literature (Cook et al., 2014; Bornkamp et al., 2017; Guo and He, 2019) that the subgroup selection bias, if not accounted for, is likely to lead to overtreatments and false discoveries.”
BackgroundSanz, M., Carrillo de Albornoz, A., Martín, C., Needleman, I., & Tonetti, M. S. (2023) · Clinical Oral Implants Research · doi:10.1111/clr.14080
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.